These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38263766)

  • 1. The detection of PD-L1 expression on liquid-based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid-based cytology and cell block samples.
    Ma H; Jia J; Sun Z; Xiao X; Liang S; Zhao L; Zhang Z
    Diagn Cytopathol; 2024 May; 52(5):235-242. PubMed ID: 38263766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
    Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
    BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant pleural effusion cell blocks are reliable resources for PD-L1 analysis in advanced lung adenocarcinomas: a concordance study with matched histologic samples.
    Mahajan S; Nambirajan A; Gupta I; Gupta N; Gupta P; Jain D
    J Am Soc Cytopathol; 2022; 11(5):253-263. PubMed ID: 35589508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
    Jain D; Sukumar S; Mohan A; Iyer VK
    Cytopathology; 2018 Dec; 29(6):550-557. PubMed ID: 29938855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
    Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of cell blocks prepared from residual pleural effusion and bronchial washing samples for immunocytochemistry.
    Harabajsa S; Milutin L; Breški A; Ražnjević K; Šimić V; Branica BV; Smojver-Ježek S
    Cytopathology; 2023 May; 34(3):264-270. PubMed ID: 36941745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
    Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
    Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistency Analysis of Programmed Death Ligand 1 Expression in Non-Small Cell Lung Cancer Between Pleural Effusion and Matched Primary Lung Cancer Tissues by Immunohistochemical Double Staining.
    Sun Z; Xiao X; Liang S; Ma H; Sun Y; Zhao L; Wang C; Chang X; Zhao H; Guo H; Zhang Z
    Lab Invest; 2024 Jun; 104(6):102058. PubMed ID: 38626874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 13. Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: Comparison of cell-blocks and matched surgical resection specimens in lung cancer.
    Pak MG; Roh MS
    Cytopathology; 2019 Nov; 30(6):578-585. PubMed ID: 31209979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
    Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
    Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma.
    Hernandez A; Brandler TC; Zhou F; Moreira AL; Schatz-Siemers N; Simsir A
    Am J Clin Pathol; 2019 Mar; 151(4):403-415. PubMed ID: 30534975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer.
    Song SG; Lee J; Koh J; Kim S; Chung DH; Jeon YK
    Diagn Cytopathol; 2020 Apr; 48(4):291-299. PubMed ID: 31930724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
    Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
    Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.